CERS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cerus Corp (CERS) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is undervalued, has strong long-term growth prospects, and analysts have a Buy rating with a significant upside potential. Despite short-term price volatility, the company's revenue growth trajectory and strategic partnerships make it a compelling investment for long-term gains.
The MACD is negative and expanding, indicating bearish momentum. RSI is at 29.209, suggesting the stock is approaching oversold territory. Moving averages are converging, reflecting indecision in the market. The stock is trading near its support level of 2.004, which could act as a potential bounce point.
Analysts highlight Cerus' Intercept Fibrinogen Complex as a long-term growth driver.
The BCA partnership is expected to accelerate adoption and profitability.
Revenue growth of 13.79% YoY in Q4 2025 demonstrates strong performance.
Analysts have a Buy rating with a price target of $5, representing significant upside potential.
The stock experienced a sharp 9.15% decline in regular market trading.
Net income dropped by 13.37% YoY, reflecting profitability challenges.
Gross margin declined by 3.54% YoY, indicating cost pressures.
In Q4 2025, revenue increased by 13.79% YoY to $64.6 million, showcasing strong top-line growth. However, net income declined by 13.37% YoY to -$2.18 million, and gross margin dropped to 56.64%, down 3.54% YoY. Operating expenses rose by 7%, driven by higher R&D and SG&A costs.
TD Cowen has a Buy rating on Cerus with a price target of $5, citing the company's strong revenue growth trajectory and undervalued stock price. Analysts view the BCA partnership as a catalyst for scalability and profitability.
